Cencora, Inc. (COR): analysis and signal as of September 6, 2026
In short
Documentary update dated 2026-09-08. Official disclosure dated 2026-08-05. Displayed signals and scores retain their own date; they are not recalculated here.
- Current signal
- moderate (vote 3/3)
- Deterministic score
- +0.5 → signal expected by the scale : weak (September 10, 2026)
- Layers
- fundamentals : positive, price : positive, risks : neutral
Triggered rules
| Rule | Weight |
|---|---|
| favors a high and durable return on invested capital (ROIC), a marker of a lasting moat | +2.0 |
| penalizes a PEG above 2, the anticipated growth is overpaid (overvalued fast grower) | -1.5 |
| penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE | -1.0 |
| moderately favors an asset with robust operating profitability (RMW factor), cross-check with accounting quality (possible manipulation) | +0.5 |
| moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger | +0.5 |
Thesis
In fiscal third quarter 2026, Cencora reported revenue of USD 84.8 billion, up 5.1%. GAAP diluted EPS was USD 3.94, compared with adjusted EPS of USD 4.48. Management raised annual adjusted EPS guidance to USD 17.75–17.95. Net interest expense reached USD 140.7 million, including the impact of financing OneOncology.
Bull case
Favourable hypothesis: sustained specialty distribution growth could support earnings if OneOncology integration proceeds successfully.
Bear case
Adverse hypothesis: financing costs and integration expenses could absorb some growth. Revenue growth alone does not establish an equivalent improvement in cash generation.
Scenarios
Qualitative scenarios: favourable if the described momentum continues; central if it stabilises; adverse if risks materialise. No probability or share price target is calculated in this review.
Risks
Items to check in upcoming disclosures: earnings conversion into cash, debt and financing costs, organic growth separately from acquisitions, and continued support for annual guidance. Quotations, valuation and announcements subsequent to the cited document still require verification. Partial or total capital loss is possible.
Verified official disclosure
Accessed on 2026-09-08; interpretations above are research hypotheses.
Market positioning (short sellers)
- Short interest / shares outstanding
- 2.58 %
- Days to cover
- 2.39
- Settlement date
- 2026-08-14
- Source
- FINRA (disseminated on 2026-08-26)
Upcoming catalysts
| Date | Description |
|---|---|
| Q4 FY2026 and fiscal 2027 guidance |
Signal history (last 12 months)
| Date | Signal | New fact |
|---|---|---|
| moderate (3/3) | not published | |
| moderate (single draw, outside the three-draw protocol) | not published | |
| moderate (single draw, outside the three-draw protocol) | unchanged |
Frequently asked questions
What is the scope of this update?
This review covers the official quarterly results cited in the report. It distinguishes reported accounts, adjusted measures and management expectations. Market prices, consensus estimates and technical indicators are not refreshed in this documentary update. It therefore does not establish a new market signal.
How should scenarios be interpreted?
The scenarios describe possible mechanisms, without numerical probabilities or share price targets. They are not established events. Monitoring them requires comparing subsequent disclosures with the stated hypotheses, also looking for contradictory evidence and changes in the economic environment that could invalidate the interpretation.
What checks remain necessary?
Links to official documents allow figures and reporting periods to be checked. Subsequent announcements, dated prices and valuation still require verification. Historical results guarantee no future performance, and partial or total capital loss remains possible. The review is a dated research document with an explicitly limited scope.
Sources
The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.
- — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers (SEC · 8-K)
- — 7.01 Regulation FD Disclosure (SEC · 8-K)
- — 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits (SEC · 8-K)
- — 10-Q (SEC · 10-Q)
Automated AI analysis: limitations and transparency
- This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
- Tool and analysis: QDNA, Aurélien Ambert.
- Analysis (arbitration) completed on September 6, 2026; this page was completed on September 8, 2026 at 21:06 (UTC).
- Interests: data consulted on (UTC) records a position held by the author in the stock analysed (COR). This consultation does not reconstruct the situation at the analysis publication date.
- This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
- Methodology: analysis chain, score formula and scale described on the public methodology page.
- Analysis horizon: 2035.
See also
- Neighbouring stock in the same sector: Arrow Electronics, Inc. (ARW)
- All analysed stocks
- Public methodology